Source:Medtech Insight's VC deal tracker
Grail had been hoping to raise around $100m more before the end of the quarter to close the series B round at over $1bn, but as this article went to press, there had been no news of any additional funding. Johnson & Johnson Innovation was the biggest investor in the $900m first tranche, with the participation of ARCH Venture Partners, as well as certain well-known names in the pharma, tech and medtech space, such as Bristol- Myers Squibb, Celgene, Merck, Amazon and Varian Medical Systems. Of course, Chinese players are now ubiquitous in these types of investments and Grail's investor from the East comes in the form of China's leading internet services provider Tencent Holdings.
Grail was spun out of Illumina last year, and – as its name indicates – is on the mission to develop a simple blood test that can screen for cancer at an early stage.
The second largest fundraising in March came from Freenome, which also has a similar focus to Grail, that being to develop liquid biopsy tests that use cell-free DNA circulating in the blood to allow earlier and better diagnosis of disease. What's commendable about Freenome's deal is that it was an impressive $65m series A, an unusually large amount for an early-stage round. Freenome also has some big tech names backing it, including Google Ventures.
Orthopedics attracted a lot of the big bucks in March, with three companies in this space featured in the month's top 5 biggest deals. (See Table 2).
Figure 2
No. of VC deals, based on product/therapy sector
Source:Medtech Insight's VC deal tracker
How the venture financing climate will look in the coming months is hard to predict. M&A activity this year to date has been very quiet, with many transactions being more about acquisitions of mid-sized assets to consolidate the buyer's presence in its respective market, rather than a technology buy to fill portfolio gaps. That said, there is a still a lot of time for the tables to turn and if Grail does complete its series B with another $100m in the bag over the next few months, and the flow of bigger buck-deals start picking up like it did for March, 2017 may end on a better note than it started.
From the editors of Clinica
Request a Trial
Pharma Report Store
